💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Interferon Gamma-1B

CHEMBL1201564 Phase 4 معتمد Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This recombinant interferon gamma is used to reduce the frequency and severity of serious infections in patients with chronic granulomatous disease (CGD), a rare immune disorder affecting the ability of white blood cells to kill certain bacteria and fungi. It enhances the killing ability of immune cells. It is also used for severe malignant osteopetrosis.

المجالات العلاجية

Melanoma Ovarian Cancer Pancreatic Cancer Respiratory Disease Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Immunology Inflammatory Bowel Disease Psoriasis Multiple Sclerosis Oncology Lymphoma Type 2 Diabetes Breast Cancer Atopic Dermatitis HIV/AIDS Hepatitis C Tuberculosis Prostate Cancer Colorectal Cancer Leukemia

آلية العمل

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This recombinant interferon gamma is used to reduce the frequency and severity of serious infections in patients with chronic granulomatous disease (CGD), a rare immune disorder affecting the ability of white blood cells to kill certain bacteria and fungi. It enhances the killing ability of immune cells. It is also used for severe malignant osteopetrosis.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Interferon Gamma-1B is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201564. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.